PL2398784T3 - Postacie krystaliczne febuksostatu - Google Patents

Postacie krystaliczne febuksostatu

Info

Publication number
PL2398784T3
PL2398784T3 PL10724664T PL10724664T PL2398784T3 PL 2398784 T3 PL2398784 T3 PL 2398784T3 PL 10724664 T PL10724664 T PL 10724664T PL 10724664 T PL10724664 T PL 10724664T PL 2398784 T3 PL2398784 T3 PL 2398784T3
Authority
PL
Poland
Prior art keywords
febuxostat
crystalline forms
crystalline
forms
Prior art date
Application number
PL10724664T
Other languages
English (en)
Inventor
Maytal Piran
Leonid Metsger
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42352168&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2398784(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of PL2398784T3 publication Critical patent/PL2398784T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
PL10724664T 2009-06-10 2010-06-10 Postacie krystaliczne febuksostatu PL2398784T3 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US18577509P 2009-06-10 2009-06-10
US22258309P 2009-07-02 2009-07-02
US23355209P 2009-08-13 2009-08-13
US23548109P 2009-08-20 2009-08-20
EP10724664A EP2398784B1 (en) 2009-06-10 2010-06-10 Crystalline forms of febuxostat
PCT/US2010/038143 WO2010144685A1 (en) 2009-06-10 2010-06-10 Crystalline forms of febuxostat

Publications (1)

Publication Number Publication Date
PL2398784T3 true PL2398784T3 (pl) 2013-07-31

Family

ID=42352168

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10724664T PL2398784T3 (pl) 2009-06-10 2010-06-10 Postacie krystaliczne febuksostatu

Country Status (13)

Country Link
US (3) US8415481B2 (pl)
EP (2) EP2532654A1 (pl)
JP (1) JP5215505B2 (pl)
KR (2) KR101310002B1 (pl)
CN (1) CN102803240A (pl)
CA (1) CA2764600A1 (pl)
DE (1) DE202010017868U1 (pl)
ES (1) ES2395381T3 (pl)
HR (1) HRP20121028T1 (pl)
IL (1) IL216648A0 (pl)
PL (1) PL2398784T3 (pl)
PT (1) PT2398784E (pl)
WO (1) WO2010144685A1 (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2764603C (en) * 2009-07-15 2017-03-14 Teijin Pharma Limited Process for producing crystals of polymorphic 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid by poor-solvent addition method
EP2536699A2 (en) * 2010-02-19 2012-12-26 Cadila Healthcare Limited Substantially pure salts of febuxostat and processes for preparation thereof
EP2399911B1 (en) 2010-06-25 2015-08-19 Sandoz Ag Polymorphs of Febuxostat
WO2012048861A1 (en) * 2010-10-14 2012-04-19 Gador S.A. A novel febuxostat crystalline form and the process for the preparation thereof
WO2012098501A1 (en) * 2011-01-21 2012-07-26 Ranbaxy Laboratories Limited Febuxostat co-crystals
EP2502920A1 (en) 2011-03-25 2012-09-26 Sandoz Ag Crystallization process of Febuxostat from A
US20140112992A1 (en) * 2011-06-06 2014-04-24 Hetero Research Foundation Process for febuxostat
CN102267957B (zh) * 2011-08-24 2013-04-24 山东齐都药业有限公司 非布司他a晶型的制备方法
WO2013076738A2 (en) 2011-11-15 2013-05-30 Mylan Laboratories Ltd Process for the preparation of febuxostat polymorphs
WO2013088449A1 (en) * 2011-12-16 2013-06-20 Natco Pharma Limited Stable crystal form of febuxostat and process for the preparation thereof
CN103044353B (zh) * 2013-01-24 2014-06-11 吉林三善恩科技开发有限公司 一种非布索坦药物共晶及其制备方法
EP2902016A1 (en) 2014-01-30 2015-08-05 Alfred E. Tiefenbacher (GmbH & Co. KG) Febuxostat tablet
EP3002006A1 (en) 2014-10-01 2016-04-06 Bluepharma - Industria Farmacêutica, S.A. Pharmaceutical composition capable for the incorporation Febuxostat in the crystalline modifications F10, II, G and A
CZ27857U1 (cs) 2014-12-12 2015-02-23 Zentiva, K.S. Formulace obsahující tuhý roztok febuxostatu
WO2016171254A1 (ja) * 2015-04-22 2016-10-27 日本ケミファ株式会社 ２－［３－シアノ－４－（２－メチルプロポキシ）フェニル］－４－メチルチアゾール－５－カルボン酸の結晶、その製造方法、及びそれらの利用
KR20180013563A (ko) * 2016-07-29 2018-02-07 한미정밀화학주식회사 고순도 결정형 페북소스타트의 개선된 제조 방법
CN106511288A (zh) * 2016-12-20 2017-03-22 天津泰普制药有限公司 一种非布司他片剂的制备方法
WO2022014397A1 (ja) * 2020-07-13 2022-01-20 日本碍子株式会社 精製方法
WO2022013919A1 (ja) * 2020-07-13 2022-01-20 日本碍子株式会社 精製方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992009279A1 (en) 1990-11-30 1992-06-11 Teijin Limited 2-arylthiazole derivative and pharmaceutical composition containing the same
PT1956014T (pt) 1998-06-19 2019-04-24 Teijin Pharma Ltd Polimorfos de ácido 2-(3-ciano-4-isobutiloxifenil)-4-metil- 5-tiazolecarboxílico e método para a sua produção
JP2003261548A (ja) * 2002-03-07 2003-09-19 Teijin Ltd ２−（３−シアノ−４−イソブチルオキシフェニル）−４−メチル−５−チアゾールカルボン酸の結晶多形体の製造方法
DK1488790T3 (da) * 2002-03-28 2014-10-13 Teijin Pharma Ltd Fast præparat indeholdende en enkeltkrystalform A af etthiazolcarboxylsyrederivat
WO2007148787A1 (ja) * 2006-06-23 2007-12-27 Teijin Pharma Limited ２－（３－シアノ－４－イソブチルオキシフェニル）－４－メチル－５－チアゾールカルボン酸の結晶多形体の製造方法
CN101139325B (zh) * 2006-09-07 2010-05-12 上海医药工业研究院 2-(3-氰基-4-异丁氧基苯基)-4-甲基-5-噻唑甲酸晶型及其制备方法
CN102093309B (zh) 2006-12-07 2012-07-04 重庆医药工业研究院有限责任公司 非布司他的晶型及其制备方法
CN1970547B (zh) * 2006-12-07 2011-04-06 重庆医药工业研究院有限责任公司 非布司他的晶型及其制备方法
CN102093308B (zh) 2006-12-07 2012-08-29 重庆医药工业研究院有限责任公司 非布司他的晶型及其制备方法
CN100546985C (zh) 2007-06-29 2009-10-07 上海华拓医药科技发展股份有限公司 非布他特微晶及其组合物
CN101412700B (zh) 2007-10-19 2011-06-08 上海医药工业研究院 非布司他的晶型及其制备方法
CN101684107A (zh) 2008-09-26 2010-03-31 上海优拓医药科技有限公司 非布索坦的新晶型及其制备方法
CN101386605B (zh) 2008-10-23 2010-09-08 中国科学院上海药物研究所 非布司他新型晶体及其制备方法
CN101759656B (zh) 2008-12-12 2013-04-03 重庆医药工业研究院有限责任公司 非布司他新晶型及其制备方法
CN101768136A (zh) 2008-12-29 2010-07-07 北京德众万全药物技术开发有限公司 一种非布索坦新晶形及其制备方法
CN101768150B (zh) 2009-01-05 2014-08-06 常州市第四制药厂有限公司 2-[3-氰基-4-异丁氧基苯基]-4-甲基噻唑-5-甲酸晶型及其制备方法
CN101805310A (zh) 2009-02-17 2010-08-18 成都威克药业有限责任公司 2-(3-氰基-4-异丁氧基苯基)-4-甲基-5-噻唑甲酸的δ-晶型、其制备方法和药物组合物
CN101857578A (zh) 2009-04-08 2010-10-13 北京海步国际医药科技发展有限公司 非布司他新晶型及制备方法
CN101684108B (zh) 2009-04-15 2012-01-11 天津市汉康医药生物技术有限公司 2-(3-氰基-4-异丁氧基苯基)-4-甲基-5-噻唑甲酸及其组合物
CN101891702B (zh) 2009-05-22 2012-07-04 重庆圣华曦药业股份有限公司 非布司他的晶体、制备方法及在药物中的应用
CN101648926B (zh) 2009-07-09 2011-11-16 石药集团欧意药业有限公司 一种非布司他晶型及其制备方法
CN101817801A (zh) 2009-08-12 2010-09-01 北京红惠新医药科技有限公司 2-(3-氰基-4-异丁氧基苯基)-4-甲基-5-噻唑甲酸新晶型k及其他晶型的制备方法
CN101671314B (zh) 2009-09-17 2011-11-23 中国药科大学 一种非布索坦的晶型体及制备方法
CN101858578B (zh) 2010-04-28 2014-06-11 海洋王照明科技股份有限公司 一种防旋转连接结构及使用该结构的灯具
WO2012048861A1 (en) 2010-10-14 2012-04-19 Gador S.A. A novel febuxostat crystalline form and the process for the preparation thereof

Also Published As

Publication number Publication date
HRP20121028T1 (hr) 2013-01-31
EP2532654A1 (en) 2012-12-12
JP2012529537A (ja) 2012-11-22
KR20120034077A (ko) 2012-04-09
US20100317702A1 (en) 2010-12-16
IL216648A0 (en) 2012-03-01
DE202010017868U1 (de) 2012-11-28
KR101310002B1 (ko) 2013-09-25
US20130178504A1 (en) 2013-07-11
CN102803240A (zh) 2012-11-28
CA2764600A1 (en) 2010-12-16
KR20120140267A (ko) 2012-12-28
EP2398784B1 (en) 2012-10-17
US8609856B2 (en) 2013-12-17
JP5215505B2 (ja) 2013-06-19
US20130245077A1 (en) 2013-09-19
ES2395381T3 (es) 2013-02-12
EP2398784A1 (en) 2011-12-28
PT2398784E (pt) 2012-12-27
WO2010144685A1 (en) 2010-12-16
US8415481B2 (en) 2013-04-09
US8742129B2 (en) 2014-06-03

Similar Documents

Publication Publication Date Title
HK1254977A1 (zh) 索非布韋(sofosbuvir)的結晶形式
IL216648A0 (en) Crystalline forms of febuxostat
HUS1800015I1 (hu) Kristályok
ZA201105462B (en) Crystalline insulin-conjugates
EP2477628A4 (en) PREPARATION OF CRYSTALLINE FORMS OF DIHYDROPYRAZOLOPYRIMIDINONE
EP2435390A4 (en) TRANSALCYLATION OF POLYCYCLOHEXYLBENZENES
EP2438246A4 (en) CONSTRUCTION ASPECTS
ZA201109045B (en) Crystalline form of pemirolast
ZA201202097B (en) Crystalline forms of substituted pyrazolopyrimidines
IL226041A0 (en) Polymorphic forms of pebuxostat
PL2399911T3 (pl) Polimorfy febuksostatu
GB0918923D0 (en) Aminothiazole derivatives
SI2398784T1 (sl) Kristalna oblika febuksostata
HUP0800755A2 (en) Crystalline forms of rosiglitazone
TWM372743U (en) Improved structure of Kendama
TWM365675U (en) Improved structure of teapoy
TH105747B (th) รูปแบบผลึกของไนโตรเคทิคอล
GB0903773D0 (en) Works of art
TWM374127U (en) Structure of three-string Huqin